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ABSTRACT
Transposons of the Tc1/mariner family have been
used to integrate foreign DNA stably into the
genome of a large variety of different cell types
and organisms. Integration is at TA dinucleotides
located essentially at random throughout the
genome, potentially leading to insertional muta-
genesis, inappropriate activation of nearby genes,
or poor expression of the transgene. Here, we
show that fusion of the zinc-finger DNA-binding
domain of Zif268 to the C-terminus of ISY100
transposase leads to highly specific integration
into TA dinucleotides positioned 6-17bp to one
side of a Zif268 binding site. We show that the
specificity of targeting can be changed using
Zif268 variants that bind to sequences from the
HIV-1 promoter, and demonstrate a bacterial
genetic screen that can be used to select for
increased levels of targeted transposition. A TA
dinucleotide flanked by two Zif268 binding sites
was efficiently targeted by our transposase-Zif268
fusion, suggesting the possibility of designer
‘Z-transposases’ that could deliver transgenic
cargoes to chosen genomic locations.
INTRODUCTION
Various strategies have been used to integrate foreign
DNA into the genomes of model and other organisms,
including homologous recombination, site-speciﬁc recom-
bination and double-strand break repair following
site-speciﬁc DNA cleavage by engineered nucleases (1).
These strategies integrate the foreign DNA into speciﬁc
locations in the host genome, but can suﬀer from low
eﬃciency or a lack of suitable integration sites.
In contrast, transposon and retroviral integration
systems act with high eﬃciency (2,3), but suﬀer from a
lack of control over the site of integration. Integration
at inappropriate genomic locations can lead to activation
or inactivation of important host genes with severe dele-
terious consequences (4). Alternatively, insertion into
regions of heterochromatin can lead to poor expression
of the foreign DNA.
Members of the Tc1/mariner family of transposable
elements are widespread in nature, being found in both
prokaryotes and eukaryotes (5). Naturally occurring
active elements from the Tc1/mariner family include
Mos1 mariner from Drosophila mauritiana (6), Tc1 and
Tc3 from Caenorhabditis elegans (7,8), and ISY100
(ISTcSa) from Synechocystis sp. PCC6803 (9,10). Other
active elements, such as Sleeping Beauty and Himar1
have been reconstructed from the sequences of multiple
inactive copies present in the genomes of ﬁsh and
insects, respectively (11,12). Transposons from the Tc1/
mariner family are highly active in cultured cells and
model organisms, and there is much interest in their use
as vectors for gene delivery (13).
One transposon from the Tc1/mariner family, the
Synechochystis transposon ISY100, transposes eﬃciently
both in vitro, and in vivo in Escherichia coli (9,10).
ISY100 has a simple structure, consisting of a single
transposase gene ﬂanked by 24bp imperfect terminal
inverted repeats (IRs) that mark the transposon ends.
Like other members of this family, ISY100 transposase
has an N-terminal DNA-binding domain that speciﬁcally
recognizes the transposon IRs, and a C-terminal DDE
domain that catalyses the cutting and rejoining reactions
involved in transposition. Transposition occurs by a cut
and paste mechanism in which the transposon is cut from
one site in the genome by double-strand breaks at both
transposon ends, and then inserted into a new target site.
Transposition is exclusively into TA dinucleotides, and
insertions are ﬂanked by duplications of this target TA.
Previous work has had some success in modifying the
target speciﬁcity of retroviral integrases and eukaryotic
transposases, by directly or indirectly tethering the
transposase to speciﬁc sites in the DNA using
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these studies, multiple binding sites for the DNA-binding
domain were required, and integration was observed
in a relatively large stretch of DNA around the speciﬁc
binding site. Here, we investigate the properties of a
‘Z-transposase’ made by fusing the zinc-ﬁnger
DNA-binding domain from the mouse transcription
factor Zif268 to the C-terminus of ISY100 transposase.
We ﬁnd that this fusion protein combines the TA
target-speciﬁcity of the Tc1/mariner family of transposases
with the DNA-binding speciﬁcity of Zif268 and promotes
transposition in speciﬁc TAs located adjacent to a single
Zif268 binding site. The target speciﬁcity of our
Z-transposase can be changed by substituting the Zif268
DNA-binding with variants that speciﬁcally recognize
sequences from the HIV-1 promoter. This system holds
great promise for the development of gene transfer
applications with precise control of the integration site.
MATERIALS AND METHODS
Donor and target plasmids
To make target plasmids for standard transposition
assays, the sequences shown in Figure 1C, ﬂanked by
HindIII and EcoRI cohesive ends, were synthesized as
oligonucleotides and inserted in the polylinker of the
5339bp plasmid pH2 (10). Papillation target plasmids
were based on the promoter probe vector pRS415 (15),
which contains four copies of the rrnB transcription
terminator upstream of an EcoRI–BamHI polylinker
and the complete lac operon. The sequence between the
BamHI site and codon 9 of lacZ was deleted from pRS415
by PCR, and papillation target sites with EcoRI and
BamHI cohesive ends were inserted in the polylinker
of the resulting vector.
Donor plasmids were based on pISY100-kan-IR30,
which has 30bp ISY100 IRR and IRL sequences
ﬂanking a kanamycin resistance determinant on the 
dv-based plasmid pCLIP18 (16). An active copy of the
ISY100 transposase gene was inserted together with lacI
q
and the trc promoter from pTrc99A (17) into
pISY100-kan-IR30, upstream of the mini-transposon,
as an SphI–XbaI fragment. To create the fusion
proteins, an EagI site was added to the transposase
gene, just before the stop codon. This adds three addi-
tional amino acids (YGR) to the C-terminus of
transposase, with no detectable eﬀect on transposition.
Synthetic fragments encoding Zif268, or ZifA or ZifB
variants of Zif268 (18), together with linker sequences
L1, L2 or L3 were inserted between EagI and KpnI sites
site at the 30-end of the transposase gene to produce the
ﬁnished donor plasmids. To make the papillation donor
plasmids, the mini-transposon was modiﬁed by the
addition of the sequence 50-gctagctcacacAGGAa
acagctATG, containing the start codon and ribosome
binding site from lacZ (uppercase) and an NheI restriction
site (underlined) just upstream of IRR30. Further details
and DNA sequences of all plasmids used in this study are
available from SDC.
Transposition assays
To carry out in vivo transposition assays, target plasmids
were introduced into the recA-deﬁcient strain DH5a using
standard CaCl2-mediated transformation. The resulting
strains were then transformed with donor plasmids using
the same method. For standard transposition assays,
transformants were selected on Luria–Bertani (LB) agar
containing 50mg/ml ampicillin, 25mg/ml chloramphenicol,
25mg/ml kanamycin, 50mM ZnSO4, and incubated for
60h at 37 C.  1000 transformant colonies were washed
from the plate in LB broth, cells were harvested by
centrifugation and plasmid DNA containing donor,
target and transposition product, was puriﬁed using
QIAprep spin miniprep kits (Qiagen). A total of 100ng
of this DNA was electroporated into DS964 (recA,
 lysogen) in which the donor plasmids cannot replicate.
A small aliquot of the electroporation mixture was diluted
10
4-fold, and spread on plates containing ampicillin to
select for target plasmids. The rest was spread undiluted
on plates containing kanamycin to select for transposition
products. The transposition frequency was calculated by
dividing the number of kanamycin resistant colonies
per millilitre of transformation mix by the number of
ampicillin-resistant colonies per millilitre.
Plasmid DNA was puriﬁed from individual
kanamycin-resistant colonies and characterised by restric-
tion digestion and DNA sequencing. To display the
overall pattern of insertion sites, plasmid DNA was
isolated from pools of  100 kanamycin-resistant
colonies, cut with BamHI and run on 1.2% agarose gels
in 50mM Tris–acetate 1mM EDTA pH 8.2 running
buﬀer. Gels were stained with ethidium bromide, DNA
was visualised by 260nm UV illumination and photo-
graphed with a Canon EOS D30 digital camera using
a 480nm band pass ﬁlter (Peca products).
For papillation assays, transformants containing donor
and target plasmids were selected on LB-agar containing
50mg/ml ampicillin, 25mg/ml chloramphenicol, 25mg/ml
kanamycin, 50mM ZnSO4, 0.1% lactose and 64mg/ml
X-gal, so as to obtain  1000 colonies per 9cm plate.
Transformants were incubated at 37 C, and photographed
every day for 6 days on a ﬂuorescent light box using
a Canon EOS D30 digital camera with no ﬁlter. Papillae
were counted in the resulting image ﬁles using the
‘threshold’ function in Adobe Photoshop followed by
‘analyze particles’ in ImageJ.
RESULTS
Target choice by wild-type transposase
Before attempting to modify the target speciﬁcity of
ISY100 transposition, we ﬁrst investigated the target
speciﬁcity of the wild-type system. The sequences of
21 ISY100 insertion sites from the Synechocystis
PCC6803 genome (19), three from the large
Synechocystis plasmids pSYSG and pSYSA (20), 19 inser-
tion sites from the work of Urasaki et al. (9), and 58
diﬀerent insertion sites generated by in vivo and in vitro
transposition into the target plasmid pH2 (10) were
analysed. All except two insertions, both from in vitro
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transposon, were in TA target sites. We could detect no
other diﬀerences in the pattern of sequences ﬂanking inser-
tions from diﬀerent sources, so all 101 insertion sites
were grouped together, aligned according to the direction
of ISY100 and compared. In addition to the TA target
sequence, there was signiﬁcant sequence preference for
the next three nucleotides on either side (Figure 1A).
The A/T-rich consensus insertion site can be summarised
as 50-ADWTAWHT (where W=A or T, D=not C and
H=not G), with the strongest preference being for A at
position  4 and T at position +4. This consensus tar-
get sequence is palindromic, suggesting that ISY100
inserts into preferred target sites with no orientation
speciﬁcity and that the left and right transposon ends
are equivalent in the integration reaction.
Design of donor and target plasmids for Z-transposition
To make Z-transposases, the DNA-binding domain from
the mouse transcription factor Zif268 was fused to the
C-terminus of ISY100 transposase (Figure 1B). Zif268
binds as a monomer with high aﬃnity and speciﬁcity to
a single asymmetric 9–10bp DNA site. It recognises its
binding site using three independently folded zinc-ﬁnger
domains, each recognising 3bp of DNA via an a-helix
inserted into the DNA major groove (21). Zinc-ﬁnger
DNA-binding proteins with novel speciﬁcities can be
assembled from libraries of modiﬁed zinc-ﬁngers selected
to bind to diﬀerent triplet sequences (22,23). Engineered
zinc-ﬁnger proteins based on Zif268 and related proteins
are now available that bind with high aﬃnity and
speciﬁcity to many diﬀerent chosen sequences, so there is
the prospect of using them to direct transposition to any
genomic target of interest.
Two short glycine- and serine-rich ﬂexible linkers
(L1, [GSG]3 and L2, [GSG]4) were used to fuse the
Zif268 DNA-binding domain to ISY100 transposase
(Figure 1B). In case these linkers were not suﬃciently
long to allow the catalytic domain of transposase to
reach TA dinucleotides adjacent to the Zif268 binding
site, a longer linker (L3), consisting of amino acids
141–185 of Tn3 resolvase and an additional 8 amino
acids (Figure 1B) was also used. To construct donor
plasmids, the genes encoding these Z-transposases, or
the control wild-type transposase, were placed adjacent
to an ISY100 mini-transposon, consisting of ISY100
left and right IRs ﬂanking a 1.3kb kanamycin resistance
determinant, on a  dv-based plasmid vector (Figure 2A).
These donor plasmids replicate normally in most E. coli
strains, but cannot replicate in  lysogens, or other strains
expressing the  repressor.
Transposase tethered to the DNA by Zif268 might be
constrained so that it can catalyse transposition into TA
targets at a ﬁxed distance from the Zif268 binding site.
To study this systematically, an array of nine copies of
the sequence [TANN] (containing nine TAs at 4bp
intervals) was placed adjacent to a 10bp Zif268 binding
site. The design of the array ensures that all except the ﬁrst
and last TA conform to the simpliﬁed ISY100 consensus
target site ANNTANNT. To obtain TAs at all possible
distances between 1 and 36bp from the Zif268 binding
site, the array was placed 0, 1, 2 or 3bp from the Zif268
binding site. Since Zif268 might direct insertions to only
one side of its asymmetric binding site, targets were
constructed with both possible orientations of the Zif268
binding site. Target sites were placed on the 5.4kb pH2,
which was used as a target plasmid in our previous
experiments with ISY100 (10). The resulting plasmids
are here referred to as pZ±X, where ‘+’ or ‘ ’ indicates
the orientation of the Zif268 binding site, and X=0 ,1 ,2
or 3 indicates the length of the spacer between the
Zif268 binding site and the ﬁrst TA of the array
(Figure 1C). Two target plasmids lacking Zif268 binding
sites were also constructed. These are identical to pZ+3
except that the Zif268 binding site (50-GCGTGGGCGT)
was changed to either 50-GACTGGGGAG or 50-GGAGC
TCTCT, giving pB+3 and pF+3, respectively. The target
plasmids all contain 340 TA dinucleotides outside of the
[TANN]9 array, and 10 inside.
Figure 1. Design of targets and chimaeric Z-transposases. (A) Sequence
summary of 101 diﬀerent ISY100 integration sites in the Synechocystis
PCC6803 genome and the target plasmid pAU5, pSEK80 and pH2.
(B) ISY100 transposase is expected to act as a dimer (27); one
monomer is coloured magenta, the other green. ISY100 transposase
contains two N-terminal helix–turn–helix domains (HTH1 and
HTH2), which recognize DNA sequences within the transposon IRs
(turquoise) and a catalytic DDE domain which integrates the IRs
into a target TA (yellow). The C-terminus of transposase was fused
to the DNA-binding domain of Zif268 (red) via three diﬀerent
linkers: L1, L2 or L3. The three zinc-ﬁngers of Zif268 are numbered
1 to 3, as are the three triplets of its recognition sequence. Note that
ﬁnger 1 recognizes triplet 3, and ﬁnger 3 recognizes triplet 1. Target
sites contain a single Zif268 binding site (blue arrow) adjacent to an
array of target TAs. The dimeric nature of Z-transposase suggests how
a second Zif268 binding site (pink arrow) could enhance the speciﬁcity
or eﬃciency of targeting. (C) Target sites for chimaeric Z-transposase
consist of a 10bp Zif268 binding site separated from a [TANN]9 array
by 0, 1, 2 or 3bp.
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In vivo transposition assays were carried out using all four
donor plasmids in all possible combinations with the
10 diﬀerent target plasmids, making a total of 40 diﬀerent
transposition assays. After incubating donor and target
plasmids together in a recA-deﬁcient E. coli strain to
allow transposition to occur, plasmid DNA, containing
a mixture of donor and target plasmids and any trans-
position product, was puriﬁed from pooled colonies.
Transposition products were isolated from this mixture by
transformation into a  lysogen strain and selecting for
kanamycin-resistant colonies. Since the donor plasmids
cannot replicate in this strain, kanamycin-resistant
colonies are only obtained if the minitransposon has
jumped from the donor to the target plasmid.
For each combination of donor and target plasmid, the
transposition frequency (the fraction of target plasmids
containing a transposon insertion) was calculated by
dividing the number of kanamycin-resistant colonies
by the number of ampicillin-resistant colonies. Averaged
overalltargetplasmids,wild-typetransposasegaveatrans-
position frequency of 1.3 10
 4, while Z-transposases
with linkers L1 ([GSG]3) and L2 ([GSG]4) gave average
transposition frequencies  3.5-fold lower (Table 1).
Z-transposase with the longer L3 linker gave transposition
at still lower frequencies,  9-fold lower than wild-type
(Table 1). For each donor plasmid, the diﬀerent target
plasmids were used with approximately equal eﬃciency,
except that L3 Z-transposase gave higher transposition
frequencies into target plasmids with the Zif268 binding
site in the ‘+’ orientation than into target plasmids
Figure 2. Targeted transposition of ISY100 by a chimaeric Z-transposase. (A) Structure of donor and target plasmids. Donor plasmids carry
a mini-ISY100 transposon encoding resistance to kanamycin, and express transposase from a hybrid trp-lac promoter under the control of the
plasmid-encoded lacI
q gene on a  dv replicon. Target plasmids carry a [TANN]9 array adjacent to a binding site for Zif268. On digestion with
BamHI, transposition products give a 1.3kb kanamycin resistance fragment and two other fragments that add up to 5.4kb. If the transposon is in
the [TANN]9 target, a 2.7kb doublet is produced. (B) Agarose gel showing BamHI-digested pooled transposition products from assays using the
indicated donor and target plasmids. The sizes of the kan
r fragment (1.3kb) and the doublet indicative of targeted transposition (2.7kb) are shown.
Lane 41 (M) contains BamHI-digested DNA from an isolated targeted transposition product.
Nucleic Acids Research,2010, Vol.38, No. 4 1207without Zif268 binding sites, or with Zif268 binding sites
in the ‘ ’ orientation (Table 1).
The distribution of mini-transposon insertions in pools
of  100 transposition products was displayed by agarose
gel electrophoresis of BamHI-digested plasmid DNA
(Figure 2B). The mini-transposon contains two BamHI
sites just inside the ISY100 IRs, while the 5.4kb target
plasmids contain a single BamHI site diametrically
opposite to the [TANN]9 target sequence (Figure 2A).
All transposition products therefore yield a 1.3kb
fragment released from the mini-transposon and two
fragments totalling 5.4kb. When the insertion is in the
[TANN]9 target array, these two fragments are both
2.7kb (Figure 2A).
As expected, wild-type transposase gave a 1.3kb
transposon fragment and a ladder of bands representing
insertions at many diﬀerent positions in all of the target
plasmids (Figure 2B, lanes 1–8). L1 and L2 Z-transposases
gave similar ladders of bands, with little or no indication
of an increase of transposition close to the Zif268 binding
site (Figure 2B, lanes 11–18 and 21–28). In target plasmids
with the Zif268 binding site in the ‘ ’ orientation
(Figure 1B), L3 Z-transposase also gave insertions at
positions distributed randomly around the target
plasmid (Figure 2B, lanes 35–38). In striking contrast,
transposition products made by L3 Z-transposase in
targets with the ‘+’ orientation of the Zif268 binding site
were strongly biased towards insertion adjacent to the
Zif268 binding site (Figure 2B, lanes 31–34). The 2.7kb
fragment, diagnostic of insertions into the [TANN]9 array,
was approximately double the intensity of the 1.3kb
transposon-derived fragment in these lanes. As the
2.7kb band is a doublet and is twice the size of the
1.3kb fragment, the relative intensity of these bands
suggests that about 50% of the insertions are in or very
close to the [TANN]9 target array.
To quantify these results more accurately, individual
transposition products were characterised by restriction
digestion.  4% of insertions by wild-type transposase
were in the [TANN]9 array (Table 2), roughly consistent
with the fraction of TAs in the target plasmid within the
array (2.6%). In contrast, nearly 50% of insertions
catalysed by L3 Z-transposase in pZ+X target plasmids
were in the TA target array (Table 2),  19 times more
than expected by chance. When the Zif268 binding site
was in the opposite orientation (in pZ-X targets) only
 9% of insertions catalysed by L3 Z-transposase were
in the TA array (Table 2).
Targeted transposition was dependent on the presence
of a functional Zif268 binding site adjacent to the
[TANN]9 array. Changing the Zif268 binding site in
pZ+3 from 50-GCGTGGGCGT to either 50-GACTGGG
GAG or 50-GGAGCTCTCT, in target plasmids pB+3 and
pF+3 respectively, abolished targeted transposition by L3
Z-transposase (Figure 2B, lanes 39 and 40), but had no
discernible eﬀect on transposition by wild-type, L1
Z-transposase, or L2 Z-transposases (Figure 2B, lanes
9,10, 19, 20, 29 and 30).
All 40 transposition assays (Table 1) were repeated
independently at least three times. In all cases, the same
results were obtained. L3 Z-transposase catalysed inser-
tion at high frequency adjacent to the Zif268 binding
site only when it was in the ‘+’ orientation, whereas
wild-type and Z-transposases with L1 and L2 linkers
catalysed transposition at many diﬀerent positions
distributed randomly throughout the target plasmids.
In transposition assays with wild-type transposase,
L1 Z-transposase, and L2 Z-transposase, some pairs of
bands adding up to 5.4kb were more intense than others
(Figure 2B). Where these bands are present in all lanes,
they presumably reﬂect preferred integration sites in the
target plasmid. Where they appear only in some lanes
(Figure 2B, lanes 16 and 25), these intense bands are
thought to reﬂect transposition events in one transformant
colony soon after the introduction of the donor plasmid
into cells containing target plasmid. These early events are
ampliﬁed during growth of the colonies in which they
occurred, and are therefore over-represented in the
pooled transposition products. In contrast to L3
Z-transposase with pZ+X targets, which always gave a
Table 1. Transposition frequencies ( 10
 6) calculated as the ratio of
kan
r/amp
r colonies as described in the text
Target Donor
Wild-type Tnp Z-Tnp L1 Z-Tnp L2 Z-Tnp L3
Z+0 143 (±18) 41 (±17) 38 (±20) 25 (±14)
Z+1 97 (±64) 44 (±19) 68 (±33) 16 (±12)
Z+2 98 (±37) 39 (±13) 56 (±33) 23 (±14)
Z+3 115 (±16) 31 (±16) 46 (±30) 17 (±9)
Z 0 128 (±42) 44 (±31) 26 (±13) 14 (±6)
Z 1 162 (±41) 52 (±29) 45 (±26) 13 (±7)
Z 2 198 (±42) 31 (±13) 34 (±19) 11 (±4)
Z 3 125 (±62) 24 (±5) 37 (±21) 12 (±5)
B+3 134 (±11) 36 (±23) 25 (±13) 12 (±10)
F+3 136 (±51) 14 (±8) 20 (±5) 8 (±4)
Average 133 (±46) 38 (±24) 41 (±26) 15 (±10)
Average frequencies (±1s) were calculated from at least three
independent experiments for each combination of donor and target
plasmids.
Table 2. Fraction of transposon inserts within [TANN]9 array
Target Donor
Wild-type L3 Z-Transposase
Z+0 0/24 12/24
Z+1 0/24 11/24
Z+2 3/24 12/24
Z+3 1/24 11/24
Z 0 2/22
Z 1 2/24
Z 2 4/24
Z 3 1/24
B+3 1/24
F+3 1/19
Approximately 24 transposition products were selected at random for
each combination of donor and target plasmid. Restriction digestion
and DNA sequencing were used to determine the number containing
inserts within the [TANN]9 array.
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tion events were diﬀerent in independent replicates of the
same experiment, reﬂecting the stochastic nature of
the assay.
In the absence of a Zif268 binding site, or when the
Zif268 binding site was in the ‘ ’ orientation, there was
no evidence that any secondary sites were used at high
frequency by L3 Z-transposase. More than 30 diﬀerent
integration sites used by L3 Z-transposase can be
identiﬁed from examination of BamHI-digested DNA
(Figure 2, lanes 35–40) and these sites seem similar to
those used by wild-type transposase (Figure 2, lanes 1–10).
Speciﬁc TAs in the [TANN]9 array are targeted
Individual transposition products containing inserts in
or close to the [TANN]9 target array were further
characterised by DNA sequencing. This conﬁrmed the
location of insertions in the [TANN]9 array, and allowed
their exact positions to be established (Figure 3).
The majority of insertions catalysed by L3 Z-transposase
in the [TANN]9 arrays of pZ+2 and pZ+3 were in the
second TA of the array (24 out of 42 insertions in pZ+2
and 34 out of 46in pZ+3), so that approximately
one-third of all insertions in these plasmids were in a
single TA 6–7bp from the Zif268 binding site. When the
[TANN]9 array was moved one or two base-pairs closer to
the Zif268 binding site, almost no insertions were in the
second TA, and instead insertions were concentrated in
the fourth and seventh (pZ+0) or the ﬁfth and seventh
(pZ+1) TAs (Figure 3). Because of the way the experiment
was carried out, the individual insertions described earlier
are not necessarily all independent. However, the results
were derived from at least four independent assays for
each combination of donor and target plasmids, and
each separate assay gave a similar distribution of insertion
site preference. When the Zif268 binding site was in the ‘ ’
orientation, only a small number of insertions in the
[TANN]9 array were obtained, but again there appeared
to be a preference for the second and seventh TAs
(Figure 3).
To see if these insertion sites were preferred because of
their position relative to the Zif268 binding site, or
because their local sequence context made them preferred
targets for the ISY100 catalytic domain, sites of insertions
in the [TANN]9 array catalysed by wild-type transposase
were also determined (Figure 3). Every TA in the
[TANN]9 array, except the ﬁrst and the ﬁfth, was used
at least once by wild-type transposase, but the two most
common integration sites were the second and seventh
(Figure 3). Therefore, although the numbers are small,
wild-type transposase appears to have a preference for
the second and seventh TAs in the array, and this
Figure 3. Distribution of insertion in the [TANN]9 array. Histograms show the number of insertions catalysed by wild-type and L3 Z-transposase
into each TA in the array. The target sequences are shown below each histogram. Arrows represent Zif268 binding sites. Note the diﬀerent
orientation of the Zif268 binding site and the diﬀerent vertical scales in left and right panels.
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L3-Z-transposase.
A papillation assay for targeted transposition
Next, a papillation assay was designed so that targeted
transposition could be followed in individual transformant
colonies. A target plasmid (pZ+3pap) was constructed with
a Zif268 binding site 3bp away from a [TANN]4 array (the
same spacing as in pZ+3) upstream of a promoterless copy
of the lacZ gene lacking its ﬁrst eight codons (Figure 4A).
The donor plasmid (pZ-DONORpap) carried the gene for
L3 Z-transposase and a modiﬁed ISY100 mini-transposon,
containing a ribosome binding site and ATG translational
start reading out through the right end of the
minitransposon (Figure 4A). Donor and target plasmids
were designed such that transposition of the modiﬁed
mini-ISY100 in the correct orientation into the second
TA of the [TANN]4 target array (the preferred TA in
pZ+3) forms a transcriptional and translational fusion,
leading to expression of functional lacZ.
Assays were carried out by introducing the donor
plasmid into cells already containing the target plasmid,
and selecting transformant colonies on solid media
containing X-gal and lactose. Transformant colonies are
expected to be white because there is no lacZ expression.
However, any cell in the colony which becomes Lac
+, due
to transposition in the correct orientation into the second
TA of the [TANN]4 array, will have a growth advantage
on the lactose-containing media and will produce a blue
minicolony (or papilla) on the otherwise colourless
colony. The number of blue papillae on a colony therefore
gives an indication of the rate of targeted transposition
within that colony.
When this assay was ﬁrst carried out with
pZ-DONORpap and pZ+3pap, only 10–20 blue papillae
were seen per plate of several thousand colonies, and no
more than one papilla was seen per colony. Transposase is
expressed from a hybrid trc-lac promoter on
pZ-DONORpap, and is repressed by the lactose repressor,
encoded by lacI on the donor plasmid (Figure 4A).
Lactose present in the papillation plates is expected to
induce transposase expression, and may lead to
‘overproduction inhibition’ of transposition, as has been
seen for other members of the Tc1/mariner/IS630 family
(24,25). To try to obtain a higher level of transposition in
the papillation assay, the region of the donor plasmid con-
taining lacI, the trp-lac promoter and the Z-transposase
gene was subjected to random mutagenesis by PCR,
and donor plasmids yielding increased numbers of blue
papillae were selected. Two such plasmids were isolated
and characterized. These mutant donor plasmids
reproducibly gave 10–100 blue papillae per colony,
increasing in number over a period of several days at
37 C. Both of these donor plasmids contained mutations
in the lacI gene (D275Y and S193L), at positions known
to give a lactose insensitive (LacI
s) phenotype (26), such
that the promoter driving expression of Z-transposase will
be repressed even in the presence of lactose. One mutant
donor plasmid (pZ-DONORpap* carrying the mutation
D275Y) was chosen for use in further experiments.
Restriction digestion and sequencing of a number of trans-
position products from blue papillae produced by
pZ-DONORpap* and pZ+3pap conﬁrmed their expected
structure, with transposon insertions in the correct
orientation in the second TA of the [TANN]4 array.
Targeted transposition is most eﬃcient 7–17bp from
the Zif268 binding site
Sequencing of targeted transposition events in the
[TANN]9 array showed that some TAs were preferred
over others (Figure 3). This appeared to be due to a
combination of preferential integration at certain
distances from the Zif268 binding site, and an inherent
preference of the catalytic domain for particular TAs in
the array. To gain more insight into this, the papillation
assay was used to investigate the eﬀect of varying
the distance between the Zif268 binding site and the
[TANN]4 array. The second TA, into which the
mini-ISY100 must insert to make a functional lacZ
fusion, is 7bp away from the Zif268 binding site in the
original papillation target plasmid (pZ+3pap; Figure 4B).
Sequences devoid of TA dinucleotides were inserted
between the Zif268 binding site and the ﬁrst TA of the
[TANN]4 array to move the target TA 8, 10, 12, 15, 17, 22
and 27bp from the Zif268 binding site in target plasmids
pZ+4pap,p Z + 6 pap...pZ+23pap (Figure 4B). A papillation
target plasmid (pZ-3pap) with the same spacing as pZ+3pap
but with the Zif268 binding site in the opposite orientation
was also constructed. Papillation assays were carried out
using these new target plasmids and the pZ-DONORpap*
donor plasmid (Figure 4C), and the results were
quantitated by counting the number of blue papillae per
plate at diﬀerent time points (Figure 4D). The results con-
ﬁrmed that targeted transposition only occurs eﬃciently
with the ‘+’ orientation of the Zif268 binding site, and that
eﬃciency of targeted transposition falls oﬀ as the target
TA is moved to 22bp or more from the Zif268 binding
site. The relatively low targeted transposition eﬃciency
when the target TA is 15bp from the Zif268 binding site
in pZ+11pap suggests there may also be helical phase
eﬀects.
Because transposases of the Tc1/mariner family act as
dimers (27), and targeted integration was observed to just
one side of the Zif268 binding site, we reasoned that two
Zif268 binding sites pointing towards each other might
direct transposition to a TA target between them (Figure
1B). A target site (ZZ) with two Zif268 binding sites, one
with same spacing as in pZ+8 and the other with the same
spacing as in pZ+3, ﬂanking a [TANN]3 array in a head-
to-head arrangement was therefore constructed (Figure
4B). As predicted, this target was an eﬃcient substrate
for targeted transposition in the papillation assay
(Figure 4C and D).
The target speciﬁcity of Z-transposase can be changed
Two engineered Zif268 variants that bind speciﬁcally to
10bp sequences from the promoter region of HIV-1 (18)
were used to alter the target speciﬁcity of Z-transposase.
Zif268-A binds speciﬁcally to the sequence 50-AGGGAG
GCGT and Zif268-B binds speciﬁcally to 50-GACTGGG
1210 Nucleic Acids Research, 2010,Vol.38, No. 4Figure 4. Papillation assays for targeted transpositon. (A) Transposition from the donor plasmid to the second TA in the [TANN]4 array upstream
of lacZ in the target plasmid creates a functional lacZ translational fusion. (B) Sequences of the diﬀerent target sites used. The Zif268 binding sites
are highlighted by blue arrows; the four TA dinucleotides in the [TANN]4 array are hi-lighted in yellow or cyan for the second TA, into which the
transposon must insert to form a functional lacZ fusion. The ZZ target contains two Zif268 binding sites ﬂanking a [TANN]3 array (C) Papillation
assays with Z-transposase donor and the diﬀerent target plasmids. (D) The histogram shows the number of papillae per plate of  1000 colonies after
3 and 4 days of incubation at 37 C. The values shown are the mean from two independent replicates; error bars represent the range between high
and low data points.
Nucleic Acids Research,2010, Vol.38, No. 4 1211GAG, with reported dissociation constants of 1.2 nM and
1.0 nM, respectively (Figure 5A). The Zif268 binding site
in the papillation target plasmid pZ+3pap was changed to
the A and B binding sites to give pA+3pap and pB+3pap
target plasmids, respectively, and the Zif268 DNA-
binding domain in the papillation donor plasmid
pDONOR-Zpap* was changed to the A and B variants
to give two new donor plasmids (pDONOR-Apap and
pDONOR-Bpap). Papillation assays were then carried
out with all combinations of donor and target plasmids
(Figure 5B). The original p-DONOR-Zpap* donor gave
the expected high number of papillae with the pZ+3pap
target plasmid but much lower numbers of papillae per
colony with the altered target plasmids. Although the
level of targeted transposition was somewhat lower
than with Z-transposase carrying the native Zif268
DNA-binding domain, A-transposase and B-transposase
preferentially catalysed targeted transposition into their
cognate target sites (Figure 5B and C), demonstrating
that the speciﬁcity of targeted transposition can be
switched using altered speciﬁcity zinc-ﬁnger variants.
DISCUSSION
In this study, we set out to create a targeted DNA inte-
gration system by combining the DNA-binding speciﬁcity
Figure 5. The speciﬁcity of targeted transposition can be changed by altering the recognition helices of the Zif268 DNA-binding domain.
(A) Sequences of recognition helices from the three ﬁngers F1, F2 and F3 of Zif268 and altered speciﬁcity mutants Zif-A and Zif-B are shown
along with the DNA sequences they recognize and their reported dissociation constants (18). (B) Papillation assays using donor and target plasmids
indicated. Plates were photographed after 5 days of incubation. (C) Charts showing the total number of papillae per plate at diﬀerent time points for
each combination of donor and target plasmid.
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the Tc1/mariner family transposon ISY100. Fusion of the
Zif268 DNA-binding domain to ISY100 transposase via
protein linker L3 reduced the overall level of transposition
into target plasmids without a Zif268 binding site by
a factor of  10 (Table 1). When the target plasmid
contained a Zif268 binding site in one orientation
adjacent to a [TANN]9 array, the transposition frequency
was partially restored, and nearly 50% of insertions were
in the [TANN]9 array.
When the Zif268 binding site was in the opposite
orientation, there was no increase in transposition and
no targeted integration was observed. It appears that
tethering the catalytic domain of transposase to the
DNA via Zif268 and the L3 linker, positions it so that
transposition takes place into TAs a short distance only
to one side of the Zif268 binding site. Zif268 binds with
a ﬁxed orientation to its asymmetric binding site, and is
expected to position the C-terminal catalytic domain
of transposase closest to the third triplet of the Zif268
binding site (Figure 6), in full agreement with the
observed orientation speciﬁcity of targeted transposition.
Although a [TANN]9 array adjacent to a Zif268 binding
site was used in some of the experiments reported here,
shorter [TANN]4 and [TANN]3 arrays were suﬃcient in
the papillation assay. We predict that any TA conforming
to the preferred target site consensus will act as an eﬃcient
target for Z-resolvase when placed at an appropriate
distance from a Zif268 binding site.
Retroviral vectors have been used extensively to inte-
grate DNA in gene therapy trials (28). Retroviral vectors
insert at many diﬀerent locations in the genome, with a
bias towards active genes. Much work has gone into the
modiﬁcation of their target speciﬁcity to avoid the
problems associated with integration at unwanted
genomic locations (29). Retroviral integrases fused to
the bacterial DNA-binding proteins LexA and the 
repressor, or to zinc-ﬁnger DNA-binding domains,
directed increased levels of integration in vitro near to
appropriate binding sites on the target DNA (30–35).
However, considerable integration still occurred at sites
distant from the desired target site, and integrase fusion
proteins were poorly incorporated into active virus parti-
cles. One lab successfully incorporated an HIV-1 integrase
zinc-ﬁnger fusion protein into infective virus particles and
obtained a 10-fold increase in integration near to the
genomic zinc-ﬁnger binding site in cultured human cells
(35). A more recent approach has been to tether the HIV-1
integrase-binding protein LEDGF/p75 to speciﬁc sites by
fusing it to a sequence-speciﬁc DNA-binding domain (36),
and a similar approach has been taken with the yeast
retrotransposon Ty5 (37).
Transposons have also been used with great success
in gene modiﬁcation applications, ﬁrst in bacteria and
invertebrates, and more recently in vertebrates (38).
However, transposons also integrate at many diﬀerent
genomic sites with possible deleterious consequences.
One widely used vertebrate transposon from the
Tc1/mariner family, Sleeping Beauty (SB), transposes
and can stably integrate transgenes in a wide variety of
eukaryotic cells. Attempts to fuse DNA-binding domains
to the C-terminus of SB transposase have led to total loss
of activity (39–41). Fusions to the N-terminus of SB
transposase retain 10–20% of wild-type activity, and one
group reported site-directed transposition in a plasmid to
plasmid transposition assay in human cells (41). An 8- to
11-fold increase in transposition into a 443bp region
around a cluster of tandemly repeated binding sites for
the DNA-binding domain used was observed. However,
transposition was not targeted to a single integration site
in the plasmid assay and no targeted transposition was
observed in genomic targets. The target speciﬁcity of the
bacterial IS30 transposase has also been successfully
modiﬁed by fusing it to two diﬀerent DNA-binding
domains (42), and similar experiments have also been
reported for the eukaryotic Mos1 and piggyBac
transposases (43). Two other approaches that have been
tried with some success for SB are: (i) tethering
the transposon DNA itself to a speciﬁc target using
a bifunctional DNA-binding protein, or (ii) using a
domain that binds tightly to transposase fused to a
DNA-binding domain to tether the transposase to the
desired target (39). This latter approach worked eﬃciently
on a chromosomal target in human cells, with  10%
of insertions in a 2.6kb target region (39).
ISY100 is from the same Tc1/mariner family as SB, but
while fusions to the C-terminus of SB transposase
completely inactivated it, C-terminal fusions of the
Figure 6. Molecular model of Z-transposase bound to the ZZ target
site. A dimer of Mos1 transposase (magenta and green cylinders; PDB
ID: 3HOT) bound to two transposon IRs (blue and turquoise) in a
paired-end complex is modeled onto the ZZ target site as B-DNA to
represent the ISY100 target-capture complex. The Zif268 binding sites
are coloured pink, the target TA is yellow and the rest of target DNA
is orange. In this view, the catalytic domain from the green monomer
sits entirely in front of the target DNA, while that of the magenta
monomer is behind. The C-terminal helical region of Mos1 transposase
absent in ISY100 transposase is shown in grey. Zif268 (red) is bound to
its two recognition sequences 7 and 12bp from the target TA. Linker
L3 (inset rainbow cylinders; from PDB ID: 1GDT) would have to
stretch 40A ˚ and 46A ˚ (dotted lines) from the predicted C-termini of
ISY100 transposase (blue) to the N-terminus of Zif268 (red sphere).
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(described above) retained 10–30% of wild-type activity
(Table 1). Examination of the recently published structure
of the Mos1 paired end complex (27) shows that the
C-terminus of Mos1 is close to the binding site for
transposon ends, and the clamp-loop linker interaction
that holds the dimeric complex together. Fusion of a
large protein domain to the C-termini of Mos1 and SB
transposases is therefore likely to interfere with binding
to the transposon ends and disrupt formation of
the paired-end complex required for catalysis. A
structure-based sequence alignment of Mos1, SB and
ISY100 transposases shows that while SB and Mos1
have similar C-termini, ISY100 lacks a C-terminal
a-helical region of 32 amino acids present in Mos1 (10).
Fusion of a protein domain to the C-terminus of ISY100
transposase therefore seems much less likely to interfere
with DNA binding and dimerization of ISY100
transposase (Figure 6). We did not attempt to fuse
a DNA-binding domain to the N-terminus of ISY100
transposase. However, because the N-terminus is further
from the catalytic target-binding domain of transposase
than the C-terminus, it seems likely that an N-terminal
fusion would not target transposition as speciﬁcally as
the C-terminal fusion studied here.
Targeted transposition required linker L3, consisting of
residues 141–185 of Tn3 resolvase. These residues form an
autonomously folding three-helix DNA-binding domain
that binds speciﬁcally to the sequence TGTCCG (44,45).
However, this sequence is not present in the ISY100 IRs
or in any of the target sequences used in our experiments.
Molecular modelling of target capture complexes formed
by Z-transposase suggest that the linker between the
C-terminus of transposase and the N-terminus of the
Zif268 DNA-binding domain will have to stretch
30–60A ˚ to allow transposase to reach target TAs
7–17bp from the Zif268 binding site (Figure 6). Linker
L3 could stretch  50A ˚ if the Tn3 resolvase
DNA-binding domain remains folded and we propose
that this linker is required simply to stretch the long dis-
tances required. Consistent with our results, molecular
modelling also suggests that steric clashes between
Zif268 and transposase will prevent integration at TAs
closer than about 6bp from the Zif268 binding site,
and that linker L3 will have to stretch right round
the DNA helix in the poorly favoured pZ+11pap target
plasmid.
L3 Z-transposase carried out a background level of
transposition at sites outside the [TANN]9 array, in
plasmids both with or without the Zif268 binding site.
This was most likely catalysed by Z-transposase molecules
interacting with target sites using solely the target binding
activity of the transposase catalytic domain. Mutations
in the transposase target-binding region, that render
transposase unable to bind target DNA without assistance
from the zinc-ﬁnger DNA-binding domain, might abolish
this undesirable oﬀ-target transposition.
We describe here a papillation assay that reports the
level of targeted transposition by Z-transposase into a
speciﬁc TA in a single bacterial colony. This assay could
be used to select Z-transposase mutants with increased
levels of targeted transposition, and could be combined
with an assay to select for loss of ‘oﬀ-target’ transposition
to obtain Z-transposase mutants with increased targeting
speciﬁcity. The overall activity of Z-transposase might
also be increased by the incorporation of ‘hyperactivity’
mutations, identiﬁed in wild-type transposase using an
assay for untargeted transposition.
To be useful for gene delivery in eukaryotic systems,
a targeted transposition system must be capable of
delivering its cargo to a single site in a genome of over
10
9bp. A 9bp zinc-ﬁnger binding site is insuﬃcient to
specify a unique site in a genome of this size, but two
9bp binding sites should suﬃce. We have observed eﬃ-
cient transposition into a TA located between two Zif268
binding sites in IR (Figure 4C). From the dimeric struc-
ture of transposase, it should be possible to select
Z-transposase variants that are dependent on zinc-ﬁnger-
mediated binding to a pair of appropriately spaced
sequence motifs for the assembly of an active dimer.
By changing the recognition helices of the zinc-ﬁnger
domains, these Z-transposases could be designed to
target many diﬀerent chosen single sites in a large
eukaryotic genome.
Z-transposase with the wild-type Zif268 domain gave
a higher level of targeted transposition than those with
Zif268 domains selected to bind to sequences from the
HIV-1 promoter (Figure 5). One possible explanation
for this is that wild-type Zif268 domain binds to its site
with a higher aﬃnity than either ZifA or ZifB variants
(18). Therefore, another approach to increasing the
speciﬁcity and eﬃciency of targeted transposition might
be to use longer, tighter binding zinc-ﬁnger proteins,
such as the synthetic polydactyl zinc-ﬁnger protein E2C.
This DNA-binding domain contains six zinc-ﬁnger
domains and binds with high aﬃnity and speciﬁcity to
an 18bp sequence that occurs just once in the human
genome (46).
We have yet to show that ISY100 transposase will
function in eukaryotic cells. Nevertheless, there is a rea-
sonable possibility that ISY100 transposase (or activated
mutants thereof) will function in eukaryotes because: (i)
ISY100 transposition requires no host speciﬁc proteins,
(ii) other members of the same family (such as Minos,
SB and derivatives of Himar1) work eﬃciently in verte-
brate cells (47) and (iii) other bacterial recombinases, such
as Cre and fC31 integrase, work eﬃciently in eukaryotic
cells and have found many useful applications. Even if
ISY100 derived Z-transposases do not function in
eukaryotic cells, the lessons learned from them using our
tractable genetic and biochemical techniques should
be applicable to other related systems.
With 50% of insertions in a 20bp region adjacent to the
Zif268 binding site, and up to 70% of these in a single TA
dinucleotide, our ISY100 Z-transposase is one of the most
speciﬁcally targeted transposition systems developed to
date. The speciﬁcity of targeting can be altered using
zinc-ﬁnger DNA-binding domains that have been
selected to bind to diﬀerent DNA sequences, and we
believe that this system holds great promise for the devel-
opment of a precisely targeted integration system that
will be useful for a number of applications.
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